BCL6 and infection: ,39 FX1 is the first reported Bcl6 inhibitor endowed with higher affinity for the Bcl6 BTB domain than the endogenous corepressors and exhibited a favorable pharmacokinetic in vivo and lack of toxicity, inflammation, or infection.40